Soleno Therapeutics (SLNO) EBITDA (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of EBITDA data on file, last reported at $31.3 million in Q1 2026.

• On a quarterly basis, EBITDA rose 168.38% year-over-year to $31.3 million in Q1 2026; TTM through Mar 2026 was $86.4 million, a 141.17% increase from a year earlier, with the FY2025 full-year figure at $9.4 million, up 105.02% from the prior year.
• EBITDA for Q1 2026 stood at $31.3 million, down from $39.6 million in the prior quarter.
• Over the last five years, EBITDA for SLNO reached as high as $39.6 million in Q4 2025 and fell as low as -$80.2 million in Q3 2024.
• Historically, EBITDA has averaged -$12.5 million across 5 years, with a median of -$8.5 million in 2023.
• Across the five-year window, EBITDA sank 672.61% in 2024 and surged 168.38% in 2026, its largest moves.
• Year by year, EBITDA stood at -$5.6 million in 2022, then slumped by 147.95% to -$13.9 million in 2023, then plunged by 324.99% to -$59.1 million in 2024, then surged by 166.95% to $39.6 million in 2025, then dropped by 20.97% to $31.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $31.3 million in Q1 2026, $39.6 million in Q4 2025, and $22.1 million in Q3 2025.